


PARKINSON DISEASE: MORE THAN MOVEMENT

- Damage to brainstem nuclei
- Reduced neurotransmitters
 - Dopamine
 - Serotonin
 - Norepinephrine
 - Acetylcholine



TODAY'S AGENDA

- How we think
 - Cognitive changes
 - Dementia
- How we act
 - Depression
 - Apathy
 - Impulses and compulsions
- What we see
 - Illusions
 - Hallucinations

HOW WE THINK——COGNITIVE CHANGES

- Causes
 - Synuclein (Lewy bodies) in cortex
 - Amyloid plaques and tau tangles, somewhat like Alzheimer disease
- Symptoms that occur in many people
 - Slower thinking
 - Poor attention and concentration
 - Difficulty multi-tasking
 - Trouble with complex reasoning
- Dementia—disabling cognitive problems (30-40%)

HOW WE THINK—COGNITIVE CHANGES

- Prevention
 - Healthy brain habits
 - Treatment of PD does not prevent cognitive changes
- Treatments
 - Change environment and habits
 - Reminders
 - Slow down and reduce multitasking
 - Occupational therapy
 - Optimize motor treatment
 - Cognitive medication—rivastigmine/Exelon (cholinesterase inhibitor)

HOW WE ACT—MOOD AND BEHAVIOR

- Directly related to neurotransmitter changes
- Can sometimes be early symptoms
- Common syndromes
 - Mood changes and major depressive disorder
 - Apathy
 - Impulse control disorders

DEPRESSION IN PARKINSON DISEASE

- The most common behavioral syndrome in PD
- Can be a presenting symptom
- O More common with:
 - More severe movement symptoms
 - Cognitive problems
 - Presence of anxiety
 - Delusions or hallucinations

DEPRESSION IN PARKINSON DISEASE

- Change in sleep pattern
- Decreased interest
- Feelings of guilt/worthlessness
- Low energy
- Reduced concentration
- Increased or reduced appetite
- Motor changes—"moving through mud" or jitteriness
- Frequently thinking about death/dying

DEPRESSION IN PD—TREATMENT

- Optimize motor symptom treatment
- Keep high activity levels
- Get good sleep
- Psychotherapy
- Antidepressant medications
 - SSRI (e.g., escitalopram, citalopram, sertraline)
 - SNRI (duloxetine, venlafaxine)
 - Others (bupropion, mirtazapine, vilazodone)
 - Tricyclic (nortriptyline, desipramine)

I'D LIKE TO TALK ABOUT APATHY, BUT WHO CARES?

- Occurs in about 50% of people with PD
- Symptoms—decreased goal-directed activity
 - Behavior (responding, starting, sticking)
 - Cognitive activity (thinking and learning)
 - Emotional engagement (lower emotional expression and reactivity)
- Not necessarily depression
- No reliable medication treatments, but stimulants may help

IMPULSE CONTROL DISORDERS

- An effect of increasing brain's dopamine activity
- Can happen with any medicine, but most common with agonists
- Affect 10-15% of people taking dopamine agonists
- Common behaviors—usually associated with "reward"
 - Gambling
 - Shopping/purchasing
 - Sexual activity
 - Eating
- o "Punding"—repetitive, stereotyped, useless behaviors

WHAT WE SEE—PERCEPTUAL DISTURBANCES

- o Occur in 25-50% of people with PD
- Vexing and persistent
- Associated with
 - Duration of PD
 - Presence of cognitive dysfunction
 - Advanced age
 - Severe motor impairment
 - Other visual problems
 - Dopamine agonist medications

VISUAL PERCEPTUAL DISTURBANCES

Illusions

- Distortions of actual sensory input
- Possibly exaggerated form of pareidolia
- Hallucinations
 - Generation of an image by the brain
 - Associated with delusions (false beliefs)
 - Insight declines over time



PERCEPTUAL DISTURBANCES IN PD—TREATMENT

- Environmental and behavioral
 - Proper sleep
 - Exercise
 - Increase real sensory input
 - Reduce ambiguities (good lighting, remove extra objects)
- Medications
 - Cholinesterase inhibitors—rivastigmine, donepezil, galantamine
 - Antipsychotic medicines—pimavanserin, clozapine, ± quetiapine, ±aripiprazole

CONCLUSION

- Parkinson disease disorders more than movement
- Non-motor symptoms are to be expected
 - Cognitive
 - Behavioral
 - Perceptual
 - Others
- Effective treatments are available
- If you don't tell us, we won't know













